Medical Marijuana Had No Impact on Amphetamine Prescribing in Medicaid

medRxiv - Pharmacology and Therapeutics Pub Date : 2024-01-30 DOI:10.1101/2024.01.27.24301085

Errien M. Williams, Mariam Camara, Jessica L. Goldhirsh, Brian J. Piper

{"title":"Medical Marijuana Had No Impact on Amphetamine Prescribing in Medicaid","authors":"Errien M. Williams, Mariam Camara, Jessica L. Goldhirsh, Brian J. Piper","doi":"10.1101/2024.01.27.24301085","DOIUrl":null,"url":null,"abstract":"Abstract: Due to the uncertainty of the health effects medical marijuana poses, states differ in their medical marijuana laws (MML). Long-term effects of marijuana are found to be like attention-deficit-hyperactive disorder (ADHD). With amphetamines being prescribed to treat ADHD symptoms we hypothesized that amphetamine prescriptions would increase in states implementing MML. The number of amphetamine prescriptions filled quarterly for each state from 2006 to 2021 were calcu-lated. States with MML and dispensaries opened before 2020 were examined and states with no MML laws were the control. Prism was utilized to visualize the data and conduct four t-tests be-tween the pre and post of MML+ versus MML- states. Three MML+ states were excluded due to limited post-MML data. Among the remaining states, 31 were MML+ and 17 were MML-. No significant differences were found in amphetamine prescribing (p > 0.30). Medical marijuana legalization did not have a statistically significant impact on amphetamine prescribing in Medicaid patients during the analyzed period. Contrary to the hypothesis, the results revealed a non-significant de-crease in prescriptions in MML+ states. Further research with recreational cannabis laws or with electronic health records is warranted. Keywords: Attention Deficit Hyperactivity Disorder; cannabis; stimulant","PeriodicalId":501447,"journal":{"name":"medRxiv - Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.01.27.24301085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: Due to the uncertainty of the health effects medical marijuana poses, states differ in their medical marijuana laws (MML). Long-term effects of marijuana are found to be like attention-deficit-hyperactive disorder (ADHD). With amphetamines being prescribed to treat ADHD symptoms we hypothesized that amphetamine prescriptions would increase in states implementing MML. The number of amphetamine prescriptions filled quarterly for each state from 2006 to 2021 were calcu-lated. States with MML and dispensaries opened before 2020 were examined and states with no MML laws were the control. Prism was utilized to visualize the data and conduct four t-tests be-tween the pre and post of MML+ versus MML- states. Three MML+ states were excluded due to limited post-MML data. Among the remaining states, 31 were MML+ and 17 were MML-. No significant differences were found in amphetamine prescribing (p > 0.30). Medical marijuana legalization did not have a statistically significant impact on amphetamine prescribing in Medicaid patients during the analyzed period. Contrary to the hypothesis, the results revealed a non-significant de-crease in prescriptions in MML+ states. Further research with recreational cannabis laws or with electronic health records is warranted. Keywords: Attention Deficit Hyperactivity Disorder; cannabis; stimulant

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

医用大麻对医疗补助中开具苯丙胺类药物处方没有影响

摘要：由于医用大麻对健康影响的不确定性，各州的医用大麻法（MML）各不相同。研究发现，大麻的长期影响类似于注意力缺陷多动障碍（ADHD）。由于苯丙胺可用于治疗多动症症状，我们假设在实施医用大麻法的州，苯丙胺处方会有所增加。我们计算了 2006 年至 2021 年各州每季度开具的苯丙胺处方数量。对 2020 年前已实施 MML 并开设药房的州进行了研究，对未实施 MML 法律的州进行了对照。使用 Prism 对数据进行可视化处理，并对 MML+ 州与 MML- 州的前后数据进行了四次 t 检验。由于 MML 后数据有限，三个 MML+ 州被排除在外。在剩下的州中，31 个州为 MML+，17 个州为 MML-。在安非他明处方方面没有发现明显差异（p > 0.30）。在分析期间，医用大麻合法化对医疗补助患者的安非他明处方没有明显的统计学影响。与假设相反，结果显示，在医用大麻合法化+州，处方量出现了非显著性减少。有必要对娱乐性大麻法律或电子健康记录进行进一步研究。关键词注意缺陷多动障碍；大麻；兴奋剂

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

medRxiv - Pharmacology and Therapeutics

自引率

0.00%

发文量